OmniAb (OABI) Non-Current Assets (2021 - 2026)
OmniAb (OABI) posted quarterly Non-Current Assets of $228.5 million for Q1 2026, down 9.53% year-over-year from $252.6 million in Q1 2025, and down 2.99% quarter-over-quarter from $235.6 million in Q4 2025.
OmniAb (OABI) Non-Current Assets (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Non-Current Assets for 6 consecutive years, with $228.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 9.53% year-over-year to $228.5 million; the TTM figure through Mar 2026 stood at $955.5 million (down 8.56% YoY), while the FY2025 annual figure was $235.6 million, down 8.49% from the prior year.
- Non-Current Assets fell to $228.5 million in Q1 2026 per OABI's latest filing, from $235.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $296.3 million in Q4 2022 and bottomed at $228.5 million in Q1 2026.
- Historically, Non-Current Assets has averaged $260.5 million across 5 years, with a median of $257.4 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets grew 23.82% — and 2026, when it dropped 9.53%.
- OmniAb's Non-Current Assets stood at $296.3 million in 2022, then slipped by 5.38% to $280.3 million in 2023, then dropped by 8.17% to $257.4 million in 2024, then declined by 8.49% to $235.6 million in 2025, then slipped by 2.99% to $228.5 million in 2026.
- Business Quant data shows OABI's Non-Current Assets at $228.5 million in Q1 2026, $235.6 million in Q4 2025, and $243.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 224.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 224.24 Mn |
| Mar 31, 2026 | 228.53 Mn |
| Dec 31, 2025 | 235.57 Mn |
| Sep 30, 2025 | 243.34 Mn |
| Jun 30, 2025 | 248.06 Mn |
| Mar 31, 2025 | 252.60 Mn |
| Dec 31, 2024 | 257.42 Mn |
| Sep 30, 2024 | 264.95 Mn |
| Jun 30, 2024 | 269.96 Mn |
| Mar 31, 2024 | 275.84 Mn |
| Dec 31, 2023 | 280.32 Mn |
| Sep 30, 2023 | 284.86 Mn |
| Jun 30, 2023 | 289.30 Mn |
| Mar 31, 2023 | 291.96 Mn |
| Dec 31, 2022 | 296.26 Mn |
| Sep 30, 2022 | 237.19 Mn |
| Jun 30, 2022 | 236.10 Mn |
| Mar 31, 2022 | 235.80 Mn |
| Dec 31, 2021 | 281.92 Mn |
| Sep 30, 2021 | 235.75 Mn |